Differences in human papillomavirus (HPV) vaccine uptake by nativity status among men aged 18–34 years
Genre
Journal ArticleDate
2019-12-01Author
Adjei Boakye, EZeng, W
Governor, S
Nagendra, S
Tobo, BB
Simpson, MC
Osazuwa-Peters, N
Subject
Foreign-bornHPV vaccine
HPV vaccine coverage
HPV-associated cancer
Human papillomavirus
Nativity status
Young adults
Permanent link to this record
http://hdl.handle.net/20.500.12613/4519
Metadata
Show full item recordDOI
10.1016/j.pmedr.2019.101010Abstract
© 2019 The Authors Annually, about 16,500 HPV-associated cancers occur in the US among men. Data regarding HPV vaccine uptake among men based on nativity status (i.e., US-versus foreign-born) is limited, yet potentially important for informing interventions. We assessed differences in HPV vaccine uptake by nativity status among men aged 18–34 years in the US. The 2014–2017 National Health Interview Survey was examined for men, aged 18–34 years (n = 14,056). HPV vaccine initiation was defined as receipt of at least one dose of the vaccine and completion as receipt of three doses. Weighted, multivariable binary logistic regression models were used to assess the association between nativity status and HPV vaccine uptake, adjusting for demographic, socioeconomic, and healthcare factors. Analyses were performed in July 2018. Overall, 17% of men self-identified as foreign-born, 9.9% of men had initiated the HPV vaccine, and 3.3% had completed the HPV vaccine. Among foreign-born men, Asians had the highest HPV vaccination rates whereas those from Indian subcontinental region had the lowest rates. After accounting for demographic, socioeconomic, and healthcare factors, compared to US-born men, foreign-born men were 46% (adjusted odds ratio = 0.54; 95% CI = 0.39–0.72) less likely to initiate the HPV vaccine but there was no difference between the two groups in terms of vaccine completion. We found that HPV vaccine uptake among men was very low overall, and foreign-born men had lower initiation compared to US-born men. Public health interventions which improve HPV vaccination need to be developed for all men, irrespective of nativity status.Citation to related work
Elsevier BVHas part
Preventive Medicine ReportsADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/4501